¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"glycogen storage disease type VII"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
  • iatrogenic disease
    ÀÇÀκ´, ÀÇ¿øº´
  • ischemic bowel disease
    ÇãÇ÷Àå¿°, ÇãÇ÷âÀÚ¿°
  • ischemic heart disease
    ÇãÇ÷½ÉÀ庴
  • immune deposit disease
    ¸é¿ªÄ§Âøº´
  • immune-complex disease
    ¸é¿ªº¹ÇÕüº´
  • immunodeficiency disease
    ¸é¿ª°áÇ̺´
  • immunological disease
    ¸é¿ªº´, ¸é¿ªÁúȯ
  • immunoproliferative disease
    ¸é¿ª¼¼Æ÷Áõ½Äº´, ¸é¿ªÁõ½ÄÁúȯ
  • imported disease
    ¼öÀÔº´
  • inclusion disease
    Æ÷ÇÔüº´, ºÀÀÔüº´
  • industrial disease
    »ê¾÷º´
  • infectious disease
    °¨¿°º´
  • inflammatory bowel disease
    ¿°ÁõâÀÚÁúȯ, ¿°Áõ¼ºÀåÁúȯ
  • idiopathic disease
    Ư¹ßº´, Ư¹ß¼ºÁúȯ
  • inherited disease
    À¯Àüº´
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
  • hyperbaric disease
    °í¾Ðº´
  • hyperendemic disease
    °ú´ÙºóµµÇ³Å亴
  • hypertensive disease
    °íÇ÷¾ÐÁúȯ
  • hypertensive heart disease
    °íÇ÷¾Ð½ÉÀ庴, °íÇ÷¾Ð½ÉÀåÁúȯ
  • hypertensive vascular disease
    °íÇ÷¾ÐÇ÷°üº´
  • iatrogenic disease
    ¿øÀÎºÒ¸íº´
  • idiopathic disease
    Ư¹ßº´, Àڹߺ´
  • immune deposit disease
    ¸é¿ªÄ§Âøº´
  • immune-complex disease
    ¸é¿ªº¹ÇÕüº´
  • immunodeficiency disease
    ¸é¿ª°áÇ̺´
  • immunological disease
    ¸é¿ªÁúȯ
  • immunoproliferative disease
    ¸é¿ª¼¼Æ÷Áõ½Äº´
  • imported disease
    ¼öÀÔº´
  • inclusion disease
    Æ÷ÇÔº´, ºÀÀÔº´
  • industrial disease
    »ê¾÷º´, Á÷¾÷º´
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
  • Letterer Siwe disease
    ·¹Å×·¯-½Ã¿þº´(~º´).
  • Letterer Siwe disease
    ·¹Å×·¯-½Ã¿þº´.
  • Lindaus disease
    ¸°µµ¿ìº´
  • Lutz s disease
    ·çÂ꺴.
  • Lyme disease
    ¶óÀÓ Áúȯ
  • Lyme disease
    ¶óÀÓº´
  • Lymes disease
    ¶óÀÓ½ºº´
  • Mareks disease virus
    ¸¶·ºº´¹ÙÀÌ·¯½º
  • Menieres disease
    ¸Þ´Ï¿¡¸£º´
  • Mikuliczs disease
    ¹ÌÄð¸®Ã÷º´
  • Mondors disease
    ¸óµµ¸£ º´
  • Mu heavy chain disease
    Mu Áß¼âÁúȯ
  • Oguchis disease
    ¿À±¸Ä¡º´
  • Osler-Weber-Rendu disease
    ¿À½½·¯-¿þ¹ö-·»µÎ¾¾ º´
  • Pagets disease
    ÆÄÁ¦Æ®º´
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
  • tuberculoid (type) leprosy
    À¯°áÇÙ³ª(׾̿ú·ÑÛ), °áÇپ糪(Ì¿ú·åÆ )
  • type A behavior
    AÇü Çൿ(ú¼ÔÑ).
  • type A encephalitis
    ±â¸é¼º ³ú¿°(ÐîØùàõÒàæú).
  • type A personality theory
    AÇü ÀΰÝÀÌ·Ð(ìÑÌ«ìµÖå).
  • type A(B) personality
  • type B encephalitis =Japanese e.
    BÇü ³ú¿°.
  • type B encephalitis =Japanese e.
    BÇü ÀϺ»³ú¿°.
  • type I << antibody excess >>
    IÇü << Ç×ü°úÀ× >>
  • type I hair cell
    Á¦ Çü Åм¼Æ÷, Á¦ Çü ¸ð¼¼Æ÷(ð¯ìéúþÙ¾á¬øà).
  • type I human t lymphotropic virus
    IÇü ÀÎ t ¸²ÇÁ¿µ¾ç¼º ¹ÙÀÌ·¯½º
  • type I hyperlipoproteinemia
    I Çü °úÁö´Ü¹éÇ÷Áõ
  • type II hair cell
    Á¦ Çü Åм¼Æ÷, Á¦IIÇü ¸ð¼¼Æ÷(ð¯ì£úþÙ¾á¬øà).
  • type II human T lymphotropic virus
    II Çü ÀÎ T ¸²ÇÁ¿µ¾ç¼º ¹ÙÀÌ·¯½º
  • type III human T lymphotropic virus
    IIIÇü ÀÎ t¸²ÇÁ¿µ¾ç¼º ¹ÙÀÌ·¯½º
  • type a encephalitis
    ±â¸é¼º ³ú¿°(ÐîØùàõÒàæú)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 15
ADV adenovirus; adventitia; Aleutian disease virus; Aujeszky disease virus
ASCVD arteriosclerotic cardiovascular disease; atherosclerotic cardiovascular disease
ASHD arteriosclerotic heart disease; atrioseptal heart disease
CCD calibration curve data; central core disease; charge-coupled device; childhood celiac disease; cleid...
CDC calculated date of confinement; cancer diagnosis center; capillary diffusion capacity; cell division...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 15
HIV-1 Anti-human immunodeficiency virus type 1
APS I Autoimmune polyendocrine syndrome type I
APS-1 Autoimmune polyglandular syndrome type 1
B-CLL B cell Type
B-CLL B type chronic lymphocytic leukaemia
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • infectious disease
    °¨¿° Áúȯ, °¨¿°¼º Áúȯ, °¨¿°º´, Àü¿°º´
    °¨¿°À» ÀÏÀ¸Å°´Â ¼÷ÁÖ´Â Á¦°¢±â º´¿øÃ¼¿¡ ´ëÇØ¼­ ƯÀ¯ÇÑ ¹ÝÀÀÀ» ³ªÅ¸³»°í ¹ÝÀÀÀÇ º´ÀûÀÎ Á¤µµ¿¡ ´ÞÇØ ÀÓ»ó Áõ»óÀÌ ³ªÅ¸³­ ÁúȯÀ» ¸»ÇÑ´Ù. °¨¿°À» ÀÏÀ¸Äѵµ ¹Ýµå½Ã ¹ßº´ÇÑ´Ù°í´Â ÇÒ ¼ö ¾ø°í ±× º´¿øÃ¼ÀÇ Á¾·ù, º´¿øÃ¼ÀÇ °¨¿°·Â¿¡ °üÇÑ ÀÎÀÚ¿Í °¨¿°ÇÑ »ýüÀÇ °¨¼ö¼º, ¸é¿ª, ±× ¹ÛÀÇ ÀúÇ׷¿¡ °üÇÑ ÀÎÀÚ¿ÍÀÇ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ¼­ °áÁ¤µÈ´Ù.
  • ischemic heart disease
    ÇãÇ÷¼º ½É Áúȯ
  • Jadassohn's disease
    ¾ß´ÙÁ¸ º´
    ¹Ý»ó ±¸Áø»ó È«ÇÇÁõ.
  • Jod-Basedow disease
    Jod-Basedow Áúȯ
    ¿ä¿Àµå À¯¹ß¼ºÀÇ °©»ó¼± ±â´É Ç×ÁøÁõ.
  • jumping disease
    ¹«µµº´
  • Kahler's disease
    Kahler º´
    ´Ù¹ß¼ºÀÇ °ñ¼öÁ¾À¸·Î ÀϹÝÀûÀÎ °ñ ¼¼Æ÷¿¡¼­ º¼ ¼ö ÀÖ´Â Á¾¾ç.
  • Kawasaki disease
    °¡¿Í»çŰ º´
    °©ÀÛ½º·± ¿­°ú Àü½Å¿¡ ¹ßÁøÀÌ ³ªÅ¸³ª´Â ¿øÀÎ ºÒ¸íÀÇ Áúȯ. 1967³â ÀϺ»¿¡¼­ óÀ½À¸·Î º¸°íµÈ µ¥¼­ ÀÌ·± º´¸íÀÌ ºÙ¾ú´Ù. È«¿ª, ¼ºÈ«¿­, dzÁø µî°ú ºñ½ÁÇÑ Áõ¼¼¸¦ º¸À̹ǷΠ°¨º°¿¡ À¯ÀÇÇØ¾ß ÇÑ´Ù. Áõ¼¼·Î´Â, ¨ç °í¿­ÀÌ 5ÀÏ ÀÌ»ó °è¼ÓµÈ´Ù. ¨è ´«ÀÌ ÃæÇ÷µÈ´Ù. ¨é ¼Õ¹Ù´Ú, ¹ß¹Ù´ÚÀÌ »¡°²°Ô ºÎ¾î¿À¸£¸é¼­ ²®ÁúÀÌ ¹þ°ÜÁø´Ù. ¨ê Àӯļ±ÀÌ º×´Â´Ù. ¨ë ÀÔ¼úÀÌ ºÓ¾îÁø´Ù. ¨ì Àü½Å ¹ßÁø Áõ¼¼ µîÀ» º¸À̴µ¥, ÀÌ °¡¿îµ¥ 5°¡Áö ÀÌ»óÀÇ Áõ¼¼¸¦ º¸À̸é ÀÌ º´À» ÀǽÉÇØ¾ß ÇÑ´Ù. ¹ÙÀÌ·¯½º °¨¿°¼³, Áß¼º ¼¼Á¦¼³, Ä­µð´Ù ¼¼±Õ¼³ µîÀÌ ¿øÀÎÀ̶ó´Â Çм³ÀÌ Á¦±âµÇ¾úÀ¸³ª È®½ÇÇÏ°Ô ¹àÇôÁöÁö ¾Ê°í ÀÖ´Ù. 90 % ÀÌ»óÀÌ 1~4¼¼ÀÇ ¿µ, À¯¾Æ±â¿¡ ¹ßº´Çϸç, ¿©¾Æº¸´Ù´Â ³²¾Æ¿¡°Ô ÁÖ·Î ¹ßº´ÇÑ´Ù. ¶ÇÇÑ ¹ßº´·üÀÌ ¼­¾çÀκ¸´Ù µ¿¾çÀο¡°Ô ³ô´Ù. ¿¹¹æ¹ýÀº ÇöÀç µû·Î ¾ø°í Áõ¼¼¸¦ º¸ÀÎ ÈÄ 2~3ÁÖ¸é ÀÚ¿¬ Ä¡À¯µÇ³ª ½ÉÀå ÇÕº´ÁõÀ» ÀÏÀ¸ÄÑ ±Þ»çÇÒ À§ÇèÀÌ ÀÖ´Â Áúº´À̱⵵ ÇÏ´Ù. µû¶ó¼­ Á¶±â¿¡ ¹ß°ßÇÏ¿© ÇÕº´ÁõÀ» ¿¹¹æÇÏ´Â °ÍÀÌ Áß¿äÇÏ´Ù. Çѱ¹¿¡¼­´Â 73³â óÀ½À¸·Î ¹ß°ßµÈ ÀÌ·¡ 91³â 1, 228¸íÀÌ ¹ßº´, º¸°íµÇ¾ú´Ù.
  • Kimura disease
    Ű¹«¶ó º´
    ûÀå³â±âÀÇ ¿©ÀÚ¿¡°Ô ÁÖ·Î ¹ß»ýµÇ´Â ¸Æ¶õ¼º Áõ½Ä¼º º´¼ÒÀÌ´Ù. µÎ°æºÎ ÇÇÇÏ Á¶Á÷À̳ª ±¸°­³» ¶Ç´Â »ó¼ø ³»Ãø¿¡¼­ Àß ¹ß»ýµÇ¸ç ÀÌÇϼ± ºÎÀ§¿¡¼­µµ ÀÚÁÖ º¸ÀδÙ. Á¶Á÷ÇÐÀûÀ¸·Î ÀÌÇü¼º Ç÷°ü ³»ÇÇ ¼¼Æ÷ÀÇ Áõ½Ä°ú ¸¸¼º ¿°Áõ ¼¼Æ÷ÀÇ Ä§À±, È£»ê±¸ÀÇ Ä§À±ÀÌ ÀÖ°í ½ÉÇϸé È£»ê±¸ ³ó¾çµµ Çü¼ºÇÏ¸ç ¸²ÇÁ Á¶Á÷ÀÇ Áõ»óÀ» º¸ÀδÙ. Ÿ¾×¼± Á¶Á÷Àº À§ÃàµÇ°í ÀÖ´Ù.
  • Lane's disease
    ·¹ÀÎ º´
    ¸¸¼º Àå Æó»öÁõ.
  • Langdon-Down's disease
    ·©µ·-´Ù¿î º´
  • Larsen-Johansson disease
    ¶ó¸£¼¾-¿äÇѽ¼ º´
  • law of prophylaxis for infectious disease
    Àü¿°º´ ¿¹¹æ¹ý
  • legal communicable disease
    ¹ýÁ¤ Àü¿°º´
    Àü¿°º´ ¿¹¹æ¹ý Á¦2Á¶ 1Ç׿¡¼­ ¿­°Å ±ÔÁ¤Çϰí ÀÖ´Â Àü¿°º´. Á¦1Á¾, Á¦2Á¾ ¹× Á¦3Á¾À¸·Î ³ª´©¾îÁø´Ù. 93³â 12¿ù ¼öÁ¤, °áÁ¤µÈ ¹ýÁ¤ Àü¿°º´Àº ¸ðµÎ 28Á¾ÀÌ´Ù. Áï, Á¦1Á¾Àº ÄÝ·¹¶ó, Æä½ºÆ®, ¹ßÁøÆ¼Çª½º, ÀåÆ¼Çª½º, ÆÄ¶óƼǪ½º, µðÇÁÅ׸®¾Æ, ¼¼±Õ¼º ÀÌÁú, Ȳ¿­, Á¦2Á¾Àº Æú¸®¿À, ¹éÀÏÇØ, È«¿ª, À¯Ç༺ ÀÌÇϼ±¿°, ÀϺ» ³ú¿°, °ø¼öº´, ¸»¶ó¸®¾Æ, ¹ßÁø¿­, ¼ºÈ«¿­, Àç±Í¿­, ¾Æ¸Þ¹Ù¼º ÀÌÁú, ¼ö¸· ±¸±Õ¼º ¼ö¸·¿°, À¯Ç༺ ÃâÇ÷¿­, ÆÄ»ódz, ÈÄõ¼º ¸é¿ª °áÇÌÁõ, ·¾Å佺ÇǶóÁõ, ¾²¾²°¡¹«½Ã º´, Á¦3Á¾Àº °áÇÙ, ¼ºº´, ³ªº´À¸·Î µÇ¾î ÀÖ´Ù. Àü¿°º´ ¿¹¹æ¹ýÀº ¹ýÁ¤ Àü¿°º´¿¡ ´ëÇÑ ÀÇ»ç, È£ÁÖ, ¼¼´ëÁÖ, ±âŸ °¢ ±â°üÀÇ ±â°üÀåÀ̳ª °æ¿µÀÚ, ±º ºÎ´ëÀå µîÀÇ ½Å°í ¹× º¸°í Àǹ«¿Í °Ç°­ Áø´Ü, ¿¹¹æ Á¢Á¾, °Ý¸®, ÀÔ¿ø Á¶Ä¡, °¢Á¾ ¿¹¹æ Á¶Ä¡ µîÀ» ±ÔÁ¤Çϰí ÀÖ´Ù.
  • Legg-Calve-Perthes disease
    ·¹±×-Ä®º£-ÆÆä¸£Å×½
  • Legionnaires'disease
    ÀçÇⱺÀÎ º´
    Legionella °¨¿°Àº »çȸ ȹµæ Æó·ÅÀÇ 3-4¹øÂ°·Î ÈçÇÑ ¿øÀÎÀÌ´Ù. ¿øÀÎÀ» Àß ¸ð¸£´Â Æó·ÅÀÇ °æ¿ì´Â ¾ðÁ¦µçÁö °í·ÁÇØ¾ß ÇÑ´Ù. ÀçÇⱺÀÎ º´Àº ¸é¿ª ÀúÇÏÀÚ¿Í Èí¿¬ÀÚ, ¸¸¼º Æó ÁúȯÀÚ¿¡¼­ Á»´õ ÈçÇÏ´Ù. ·¹Áö¿À³Ú¶óÁõÀÇ Áý´Ü ¹ß»ýÀº »þ¿ö±â³ª ¼öµµ²ÀÁö¿Í ¿¡¾îÄÁÀÇ ³Ã°¢ ž°ú °°Àº ¿À¿°µÈ ¼ö¿ø°ú ¿¬°üµÇ¾î ÀÖ´Ù. ÀÌ º´Àº °´´ãÀÇ ±×¶÷ ¿°»ö¿¡¼­ ±ÕÀÌ º¸ÀÌÁö ¾Ê±â ¶§¹®¿¡ ÈçÈ÷ ºñÁ¤Çü Æó·ÅÀ̶ó°í ÇÑ´Ù. ±×·¯³ª ÀÌ º´ÀÇ ÀÓ»ó Áõ»óÀº °í¿­°ú Áßµ¶¼º ¿Ü°ß, ´Á¸·¿°, È­³ó¼º °´´ã
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 15
type II interferon <chemical> The major interferon produced by mitogenically or antigenically stimulated lymphocytes. It is structurally different from type I interferon (interferon type I) and its major activity is immunoregulation. It has been implicated in the expression of class II histocompatibility antigens in cells that do not normally produce them, leading to autoimmune disease.
Pharmacological action: antineoplastic agent, antiviral agents.
Chemical name: Interferon-gamma (human lymphocyte protein moiety reduced)
(12 Dec 1998)
type II mortality <epidemiology> A mortality schedule in which all hosts are assumed to die at a constant rate. This constant rate is equal to the inverse of the life expectancy.
(05 Dec 1998)
type II mucopolysaccharidosis <syndrome> An error of mucopolysaccharide metabolism characterised by deficiency of iduronate sulfatase, with excretion of dermatan sulfate and heparan sulfate in the urine; clinically similar to Hurler's syndrome but distinguished by less severe skeletal changes, no corneal clouding, and X-linked recessive inheritance.
Synonym: type II mucopolysaccharidosis.
(05 Mar 2000)
type I interferon <chemical> Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (interferon-alpha and interferon-beta).
Pharmacological action: antineoplastic agent, antiviral agents.
(12 Dec 1998)
type I mortality <epidemiology> A mortality schedule in which all hosts are assumed to live for a fixed number of years equal to the life expectancy.
(05 Dec 1998)
type IS mucopolysaccharidosis <syndrome> A hereditary metabolic disorder caused by a recessive gene which results in a deficiency of the enzyme alpha-L-iduronidase, which breaks down dermatan sulphate and heparan sulphate, two types of mucopolysaccharides (complex carbohydrates). Consequently, the mucopolysaccharides accumulate in the cells of the body and cause damage.
Symptoms include skeletal deformities, mental retardation, coronary artery disease, deafness, and stiff joints, among other things. There are mild and severe forms of the syndrome, the severe form is called Hurler syndrome, the mild form is called Scheie Syndrome, and children with an intermediate form have Hurler-Scheie Syndrome. Patients with the mild form generally suffer little to no mental retardation and survive to adulthood. There is presently no cure. Scheie's Syndrome is one of a number of related rare genetic mucopolysaccharide disorders, the most common being Hunter syndrome.
(09 Oct 1997)
type IVA,B mucopolysaccharidosis <syndrome> An error of mucopolysaccharide metabolism with excretion of keratan sulfate in urine; characterised by severe skeletal defects with short stature, severe deformity of spine and thorax, long bones with irregular epiphyses but with shafts of normal length, enlarged joints, flaccid ligaments, and waddling gait; autosomal recessive inheritance; type IV A mucopolysaccharidosis is due to an absence of galactose-1-sulfatase, while type IV B is due to a deficiency of a beta-galactosidase.
Synonym: Brailsford-Morquio disease, Morquio's disease, Morquio-Ullrich disease, type IVA, B mucopolysaccharidosis.
(05 Mar 2000)
type IV acrocephalosyndactyly Acrocephalosyndactyly with pointed nose, hypertelorism, cleft palate, congenital heart disease and pseudohermaphroditism; contractures of elbows and knees; soft tissue syndactyly, absent first metatarsal and great toe. Autosomal recessive.
(05 Mar 2000)
type IV collagen A less distinctly fibrillar form of collagen characteristic of basement membranes.
(05 Mar 2000)
type IV familial hyperlipoproteinaemia Plasma levels of VLDL, pre-beta-lipoproteins and triglycerides are increased on a normal diet, but beta-lipoproteins, cholesterol, and phospholipids are normal; hypertriglyceridemia is induced by a high carbohydrate diet; may be accompanied by abnormal glucose tolerance and susceptibility to ischemic heart disease; probably autosomal recessive inheritance.
Synonym: carbohydrate-induced hyperlipaemia, familial hyperprebetalipoproteinaemia, familial hypertriglyceridemia.
(05 Mar 2000)
type IV prepilin peptidase <enzyme> Product of the pulc-o pullulanase secretion gene operon; involved in processing prepilin signal peptide; may also function as an n-methyltransferase
Registry number: EC 3.4.99.-
Synonym: pulo protein, pulo gene product, pulo peptidase
(26 Jun 1999)
type locality <zoology> The geographical location of the occurrence of the population from which the type specimen was taken. Population occurring at type locality = topotypical population. Specimens collected at type locality = topotypes.
(09 Jan 1998)
type material <zoology> A collective term for all type specimens. Zoologists should ensure that such material is transferred as quickly as possible to public institutions where their safety is guaranteed and they are accessible to other workers.
(09 Jan 1998)
type series <zoology> The series of specimens which either constitutes the name-bearing type of a nominal species or subspecies or from which the name-bearing type has been or may be designated.
(09 Jan 1998)
type species <zoology> The nominal species that is the name-bearing type of a nominal genus or subgenus.
(09 Jan 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 15
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 15
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 15
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 15
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 15
ÅëÇÕ°Ë»ö ¿Ï·á